Esperion Therapeutis.Inc. sell nvestor
Start price
18.03.23
/
50%
€1.46
Target price
18.03.24
€1.00
Performance (%)
-1.58%
End price
01.04.23
€1.43
Summary
This prediction ended on 01.04.23 with a price of €1.43. With a performance of -1.58%, the SELL prediction for Esperion Therapeutis.Inc. by nvestor was down slightly. nvestor has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 3.723% | 3.723% | 93.037% | 49.341% |
| iShares Core DAX® | 0.985% | 8.314% | 7.032% | 49.791% |
| iShares Nasdaq 100 | 2.067% | 16.765% | 35.952% | 96.632% |
| iShares Nikkei 225® | 2.270% | 15.605% | 46.568% | 69.047% |
| iShares S&P 500 | 1.043% | 11.077% | 26.456% | 68.087% |
Comments by nvestor for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.